Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX extension study for crow's feet lines and glabellar lines
2010-021271-83Phase 3Completed
- Sponsor
- Allergan
- Start
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Rhytidosis facialis, lateral canthal rhytides, glabellar furrowing and 1 more comparing BOTOX with Placebo (2 arms). Primary endpoints: Investigator-assessed responder rate for crow's feet lines at maximum smile on Day 30 after first treatment cycle and Subject-assessed responder rate for crow's feet lines at maximum smile on Day 30 after first treatment cycle. Started Dec 2010; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Rhytidosis facialislateral canthal rhytidesglabellar furrowingwrinkly skin syndrome (WSS)
Beyond the preview
Go deeper on 2010-021271-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021271-83.